Oncology Conference update 

Highlights from ESMO 2025

Experts join us at ESMO 2025 to share their views on new data on GU, lung, breast, gynecological and upper GI cancers

Dr Herbert Loong

Dr Herbert Loong
Prof. Viktor Grünwald

Prof. Viktor Grünwald
Prof. Thomas Powles

Prof. Thomas Powles
Dr Elisa Agostinetto

Dr Elisa Agostinetto
Prof. Nicoletta Colombo

Prof. Nicoletta Colombo
Dr Elizabeth Smyth

Dr Elizabeth Smyth
Publication Date

Oct 2025

info Summary and next episodes download Downloadable resources
info Summary and next episodes download Downloadable resources

Prof. Viktor Grünwald joined us at ESMO 2025 to share his insights into how new data presented at the meeting may impact clinical practice. 

 

Watch the video update to hear Prof. Grünwald report on advanced renal cell carcinoma data from the LenCabo, KEYMAKER-U03 and CLEAR studies and review the use of [68 Ga]Ga-DPI-4452 for staging of disease.

 

  • LenCabo: A randomised, phase 2, multicentre trial of lenvatinib plus everolimus vs cabozantinib in patients with metastatic ccRCC that progressed on PD-1 immune checkpoint inhibition. Hahn A, et al.  Abstract LBA94, ESMO 2025 
  • KEYMAKER-U03: First-line pembrolizumab-based regimens for advanced ccRCC: substudy 03A. Suarez Rodriguez C, et al. Abstract LBA96, ESMO 2025 
  • CLEAR: Final analysis of lenvatinib + pembrolizumab vs sunitinib in patients with aRCC with or without bone metastases in CLEAR. Porta CG, et al. Abstract 2603P, ESMO 2025 
  • CAIX PET/CT: [68Ga]Ga-DPI-4452 (CAIX) PET/CT for staging of patients with ccRCC. Küper AT, et al. Abstract 2597MO, ESMO 2025

 

Clinical takeaways

  • LenCabo: demonstrates the efficacy of lenvatinib + everolimus for ICI pre-treated RCC patients with improved PFS & ORR compared with cabozantinib, although with higher toxicity. This combination should be considered for patients needing rapid or high tumour response, for whom the higher toxicity rate is acceptable
  • CLEAR: Lenvatinib + pembrolizumab demonstrated improved efficacy versus sunitinib in advanced RCC, regardless of the presence or absence of bone metastases and continues to be a standard of care treatment in this population
  • KEYMAKER-U03: Among various combinations tested, adding belzutifan (a HIF-2α inhibitor) to lenvatinib and pembrolizumab was the only regimen with improved PFS, response durability, and OS—supporting advancement to phase 3 trials as a promising new triplet for 1st-line RCC
  • CAIX PET/CT: Ga-DPI PET provides high-resolution, tumour-specific imaging in clear cell RCC, enhancing distinction between oligometastatic and widespread disease and enabling more precise selection for multimodality treatments

 

View or download Prof. Grünwald's accompanying slides for more detailed insights.

  • Understand the latest clinical trial data in advanced RCC and potential implications for patient management 
  • Recognise and determine the appropriate placement and combination of therapies for the treatment of advanced RCC 

Viktor Grünwald is a professor for Interdisciplinary Genitourinary Oncology at the University Hospital Essen in Essen, Germany. Professor Grünwald specialises in Internal Medicine and Medical Oncology. His main areas of research interest are in GU cancers, soft tissue sarcomas, head and neck cancers, with an emphasis on the academic development and translational research of immunotherapies in these indications.

Professor Grünwald graduated from the Medical School Hannover in 1998, after which he was appointed as a Private Lecturer and later professor for Haematology and Oncology at the same institution. He became professor for Interdisciplinary Genitourinary Oncology at the University Hospital Essen in 2018, thereby chairing the section for medical treatments of GU cancers.

Professor Grünwald served at the steering committee for genitourinary (GU) cancers (non-prostate) at the ESMO and ESMO ASIA Congress and was part of scientific committees of the International Kidney Cancer Symposium (EIKCS), German Cancer Congress (DKK) and the German Society for Haematology and Oncology (DGHO). He has chaired different working groups in academic organizations, such as the Central European Society of Anticancer Drug Research (CESAR) studies group, German Medical Oncology studies group (AIO) and German Cancer Society (DKG). His training activities include ESMO preceptorships and the ECCO-AACR-EORTC-ESMO workshop on methods in clinical cancer research (MCCR).

Prof. Viktor Grünwald has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, AstraZeneca, Astellas, BMS, Debiopharm, Gilead, Eisai, Ipsen, Johnson & Johnson, Merck, MSD, Novartis/AAA, Oncorena, Pfizer, Telix Pharmaceutical, Recordati, Roche and Synthekine. 
pdf Download slides - PDF clock
pdf Download slides - PPTX clock

Viktor Grünwald is a professor for Interdisciplinary Genitourinary Oncology at the University Hospital Essen in Essen, Germany. Professor Grünwald specialises in Internal Medicine and Medical Oncology. His main areas of research interest are in GU cancers, soft tissue sarcomas, head and neck cancers, with an emphasis on the academic development and translational research of immunotherapies in these indications.

Professor Grünwald graduated from the Medical School Hannover in 1998, after which he was appointed as a Private Lecturer and later professor for Haematology and Oncology at the same institution. He became professor for Interdisciplinary Genitourinary Oncology at the University Hospital Essen in 2018, thereby chairing the section for medical treatments of GU cancers.

Professor Grünwald served at the steering committee for genitourinary (GU) cancers (non-prostate) at the ESMO and ESMO ASIA Congress and was part of scientific committees of the International Kidney Cancer Symposium (EIKCS), German Cancer Congress (DKK) and the German Society for Haematology and Oncology (DGHO). He has chaired different working groups in academic organizations, such as the Central European Society of Anticancer Drug Research (CESAR) studies group, German Medical Oncology studies group (AIO) and German Cancer Society (DKG). His training activities include ESMO preceptorships and the ECCO-AACR-EORTC-ESMO workshop on methods in clinical cancer research (MCCR).

Prof. Viktor Grünwald has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, AstraZeneca, Astellas, BMS, Debiopharm, Gilead, Eisai, Ipsen, Johnson & Johnson, Merck, MSD, Novartis/AAA, Oncorena, Pfizer, Telix Pharmaceutical, Recordati, Roche and Synthekine. 
pdf Download slides - PDF clock
pdf Download slides - PPTX clock

Prof. Thomas Powles, renowned Professor of GU Oncology and Director at Bart's Cancer Centre, London, joined us at ESMO 2025 to share an update on bladder cancer.

Prof. Powles reviews the latest data from the congress, and reveals his expert views on the potential impact on clinical practice.

 

Prof. Powles talks us through data from the following studies:

 

  • KEYNOTE-905: Perioperative enfortumab vedotin plus pembrolizumab in participants with muscle-invasive bladder cancer who are cisplatin-ineligible: The phase 3 study. Vulsteke C, et al. Abstract LBA2, ESMO 2025
  • ALBAN: A phase 3, randomised, open-label, international study of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) vs BCG alone in BCG-naïve high-risk, non-muscle-invasive bladder cancer. Roupret M, et al. Abstract LBA107, ESMO 2025
  • IMvigor011: a phase 3 trial of circulating tumour DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer. Powles T.B, et al. Abstract LBA8, ESMO 2025

Programme summary
Watch the video now
Share this programme
x-twitter
This programme is financially supported by an independent educational grant from Eisai Europe Limited. Eisai has financially contributed towards this material as a sponsor and has had no influence in its organisation or creation.
Supporter Acknowledgement
This programme is financially supported by an independent educational grant from Eisai Europe Limited. Eisai has financially contributed towards this material as a sponsor and has had no influence in its organisation or creation.
Endorsement
Kidney Cancer Association EAUN
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved
Programme summary
Share this programme
x-twitter
This programme is financially supported by an independent educational grant from Eisai Europe Limited. Eisai has financially contributed towards this material as a sponsor and has had no influence in its organisation or creation.
Supporter Acknowledgement
This programme is financially supported by an independent educational grant from Eisai Europe Limited. Eisai has financially contributed towards this material as a sponsor and has had no influence in its organisation or creation.
Endorsement
Kidney Cancer Association EAUN
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved
Programme summary
  • clock Duration 2 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
x-twitter
This educational programme is supported by COR2ED.
Supporter Acknowledgement
This educational programme is supported by COR2ED.
Endorsement
EAUN
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved
info Summary and next episodes download Downloadable resources

Dr Herbert Loong joined us in Berlin to share his perspectives on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ESMO 2025.

 

Dr Loong reviews data from the following studies:

  • OptiTROP-Lung04: Sacituzumab tirumotecan vs platinum-based chemotherapy in EGFR-mutated NSCLC following progression on EGFR-TKIs: results from a randomised, multi-centre, phase 3 study. Zhang L, et al.  Abstract LBA5, ESMO 2025 
  • SOHO-01: Sevabertinib (BAY 2927088) in advanced HER2-mutant NSCLC. Le X, et al.  Abstract LBA75, ESMO 2025 
  • Beamion LUNG 1: Zongertinib as 1st line treatment in patients with advanced HER2-mutant NSCLC. Popat S, et al.  Abstract LBA74, ESMO 2025 
  • LOXO-RAS-20001:  Intracranial efficacy of olomorasib, a 2nd generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases. Cassier P, et al.  Abstract 1846MO, ESMO 2025
  • FURMO-003: Phase 2 study of firmonertinib in patients with previously treated advanced or mNSCLC with EGFR Exon 20 insertion mutations. Liu Y, et al.  Abstract 1848MO, ESMO 2025

 

Clinical Takeaways

  • SOHO-01: Sevabertinib produces rapid, durable, and clinically meaningful responses with manageable toxicity in pretreated and treatment-naïve patients with advanced HER2-mutant NSCLC. These results support sevabertinib as a potential new oral targeted therapy for this molecular subset
  • Beamion LUNG1: Zongertinib demonstrates strong and clinically meaningful efficacy with manageable toxicity, supporting its role as a targeted treatment option for HER2-driven NSCLC
  • LOXO-RAS-20001: Olomorasib provides evidence of meaningful intracranial activity, highlighting progress in addressing brain metastases in patients with KRAS G12C-mutant NSCLC and active, untreated brain metastases
  • FURMO-003: Firmonertinib continues to show promising clinical activity in EGFR exon 20 insertion (ex20ins) NSCLC, with an acceptable safety profile and ongoing phase 3 development
  • OptiTROP-Lung04: Sacitizumab tirumotecan (sac-TMT) demonstrated statistically significant and clinically meaningful improvements in PFS and OS compared to platinum-based chemotherapy (PBC) providing support for sac-TMT as a potential new treatment option for patients with EGFR-mutant NSCLC and EGFR-TKI resistance

View or download Dr Loongs's accompanying slides for more detailed insights.

  • Understand the clinical trial data and emerging profiles of therapies for the treatment of molecularly driven lung cancer, including treatments for HER2-directed NSCLC

Dr Herbert H. Loong holds conjoint appointments of Clinical Associate Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase 1 Clinical Trials Centre of The Chinese University of Hong Kong.

 

Dr Loong obtained his medical degree with a Distinction in Surgery from The University of Hong Kong in 2003. He has completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a focus on Experimental Therapeutics. His clinical and research interests include Thoracic Oncology, Sarcoma Medical Oncology and Health Economics.

 

Dr Loong is a recipient of the European Cancer Congress Fellowship Grant (2013), the American Society of Clinical Oncology (ASCO) Annual Meeting Merit Award (2014), the Hong Kong College of Physicians Young Investigators’ Award (2014). Dr. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018.

 

In recent years, Dr Loong has co-founded the Asia Pacific Oncology Drug Development Consortium (APODDC) and the Asia Pacific Coalition Against Lung Cancer (APCLC).

 

Dr Loong has served or continues to serve in various capacities in various professional international oncology bodies, including the International Affairs Committee and the Asia-Pacific Regional Council of ASCO, the Membership, Education and Communications Committees of the IASLC. He is the incoming Chairman of the International Affairs Committee of ASCO in 2024. He has been elected as a Board Member of the Connective Tissue Oncology Society (CTOS) for 2022-2024. In his prior appointment as a member of Pharmacy and Poisons Board of Hong Kong, he oversaw the registration of medicinal products and clinical trials in the territory.

Dr Herbert Loong has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AbbVie, Amgen, Bayer, Boehringer-Ingelheim, Celgene, Eisai, Eli-Lilly, George Clinical, Guardant Health, Illumina, Janssen, Novartis, Merck Sereno, Pfizer, Takeda
pdf Download slides - PDF clock
pdf Downlaod slides - PPTX clock

Dr Herbert H. Loong holds conjoint appointments of Clinical Associate Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase 1 Clinical Trials Centre of The Chinese University of Hong Kong.

 

Dr Loong obtained his medical degree with a Distinction in Surgery from The University of Hong Kong in 2003. He has completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a focus on Experimental Therapeutics. His clinical and research interests include Thoracic Oncology, Sarcoma Medical Oncology and Health Economics.

 

Dr Loong is a recipient of the European Cancer Congress Fellowship Grant (2013), the American Society of Clinical Oncology (ASCO) Annual Meeting Merit Award (2014), the Hong Kong College of Physicians Young Investigators’ Award (2014). Dr. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018.

 

In recent years, Dr Loong has co-founded the Asia Pacific Oncology Drug Development Consortium (APODDC) and the Asia Pacific Coalition Against Lung Cancer (APCLC).

 

Dr Loong has served or continues to serve in various capacities in various professional international oncology bodies, including the International Affairs Committee and the Asia-Pacific Regional Council of ASCO, the Membership, Education and Communications Committees of the IASLC. He is the incoming Chairman of the International Affairs Committee of ASCO in 2024. He has been elected as a Board Member of the Connective Tissue Oncology Society (CTOS) for 2022-2024. In his prior appointment as a member of Pharmacy and Poisons Board of Hong Kong, he oversaw the registration of medicinal products and clinical trials in the territory.

Dr Herbert Loong has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AbbVie, Amgen, Bayer, Boehringer-Ingelheim, Celgene, Eisai, Eli-Lilly, George Clinical, Guardant Health, Illumina, Janssen, Novartis, Merck Sereno, Pfizer, Takeda
pdf Download slides - PDF clock
pdf Download slides - PPTX clock
Programme summary
Watch the video now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
Endorsement
Exon20group ICAN international cancer advocacy network
Biomarker Collaborative
Lung Cancer Europe
ISLB
Lung Cancer Research Foundation
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LUNG CONNECT

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories and Boehringer Ingelheim.

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Meet the experts Independent IME approved
Programme summary
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
Endorsement
Lung Cancer Research Foundation
Exon20group ICAN international cancer advocacy network
Biomarker Collaborative ISLB
Lung Cancer Europe
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LUNG CONNECT

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories and Boehringer Ingelheim.

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Meet the experts Independent IME approved
info Summary and next episodes download Downloadable resources

Dr Elisa Agostinetto shares her perspectives on the latest breast cancer data emerging from ESMO 2025 as she reviews new data from the following studies:

 

  • monarchE: Primary overall survival results of adjuvant abemaciclib + endocrine therapy for HR+, HER2-, high-risk early breast cancer. Johnston S.R, et al. Abstract LBA13, ESMO 2025
  • DESTINY-Breast05: Trastuzumab deruxtecan vs trastuzumab emtansine in patients with high-risk HER2+ primary breast cancer with residual invasive disease after neoadjuvant therapy: Interim analysis. Geyer C.E, et al. Abstract LBA1, ESMO 2025
  • DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel + trastuzumab + pertuzumab vs SOC for high-risk HER2+ early breast cancer. Harbeck N, et al. Abstract 291O, ESMO 2025
  • ASCENT-03: Primary results from a randomised phase 3 study of sacituzumab govitecan vs chemotherapy in patients with previously untreated advanced triple-negative breast cancer who are unable to receive PD-(L)1 inhibitors. Cortés J.C, et al. Abstract LBA20, ESMO 2025
  • TROPION-Breast02: 1st line datopotamab deruxtecan vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer for whom immunotherapy was not an option: Primary results from the randomised, phase 3 TROPION-Breast02 trial. Dent R.A, et al. Abstract LBA21, ESMO 2025

 

 

How will these data impact clinical practice? Watch the video to find out!

Dr Elisa Agostinetto is a medical oncologist and leading researcher in the field of breast cancer. She received her medical degree in Italy, at University of Udine. She completed her training in medical oncology in Milan, Italy, and afterwards she moved to Brussels, Belgium, where she is currently pursuing an advanced research fellowship at Institut Jules Bordet - Université Libre de Bruxelles.

Dr Elisa Agostinetto has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Eli Lilly, Sandoz, AstraZeneca; support for conference attendence from Novartis, Roche, Eli Lilly, Genetic, Istituto Gentili, Daiichi Sankyo, AstraZeneca and a research grant to her institution from Gilead.

Prof. Nicoletta Colombo joined us at ESMO 2025 to share her insights into gynecological cancer data as they were presented at the congress.

 

Prof. Colombo reports on endometrial cancer and ovarian cancer, and reviews the following key studies:

 

  • ENGOT-ov65/KEYNOTE-B96: Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomised double-blind phase 3 study. Colombo N, et al. Abstract LBA3, ESMO 2025
  • AtTEnd/ENGOT-EN7: Final overall survival results from the randomised double-blind phase 3 trial evaluating atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. Barrentina Ginesta M.P, et al. Abstract LBA39, ESMO 2025
  • REJOICE-Ovarian01: Raludotatug deruxtecan in patients with platinum-resistant ovarian cancer: primary analysis of the phase 2 dose-optimisation part of REJOICE-Ovarian01. Ray-Coquard I.L, et al. Abstract LAB42, ESMO 2025

 

Watch the video to discover how these developments could change clinical practice!

Programme summary
  • clock Duration 4 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
x-twitter
This educational programme is supported by COR2ED.
Supporter Acknowledgement
This educational programme is supported by COR2ED.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved
Programme summary
  • clock Duration 5 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
x-twitter
This educational programme is supported by COR2ED.
Supporter Acknowledgement
This educational programme is supported by COR2ED.
Endorsement
ICAN international cancer advocacy network
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
OBSTETRICS & GYNECOLOGY CONNECT 

OBSTETRICS & GYNECOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Eisai Europe Ltd, Aspivix and Novo Nordisk.

Meet the experts Independent IME approved
info Summary and next episodes download Downloadable resources

Dr Lizzy Smyth joined us in Berlin to share her perspectives on the latest gastric and gastroesophageal data presented at ESMO 2025. 

 

Dr Smyth reviews key data from the MATTERHORN study and tells us how she thinks it will impact clinical practice:

 

  • MATTERHORN: Event-free survival with pathological outcomes: a randomised, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric/gastroesophageal junction adenocarcinoma. Tabernero J, et al. Abstract LBA81, ESMO 2025

 

 

Elizabeth (Lizzy) Smyth is a consultant in gastrointestinal oncology. Dr Smyth commenced her oncology training in Dublin, Ireland. In 2009 she was awarded a fellowship from the Irish Society of Medical Oncology to train at Memorial Sloan-Kettering Centre, New York. Following this, she worked at the Royal Marsden Hospital in London from 2011-2018. Her research focus is on clinical trials and translational research in gastroesophageal cancer, and she has worked on trial design and management of national and international trials. She is a member of the European Society for Medical Oncology GI Faculty and leads the EORTC GI Trials Group Gastric Cancer Taskforce. Dr Smyth is committed to furthering national and international collaboration in GI trials research.

Dr Elizabeth Smyth has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Grants from Bristol-Myers Squibb and Astra Zeneca, personal fees from Amgen, Astellas, Astra Zeneca, Beigene, Bristol-Myers Squibb, Daiichi Sankyo, Merck, Mirati, Novartis, Pfizer, Viracta, and Zymeworks. Chair of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group (2024–26), and has been trustee of the UK & Ireland Oesophagogastric Cancer Group since 2022; and is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre
Programme summary
  • clock Duration 1 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
x-twitter
This educational programme is supported by COR2ED.
Supporter Acknowledgement
This educational programme is supported by COR2ED.
Endorsement
DiCE
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts
Brought to you by
GI NURSES CONNECT

GI NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

podcast Video podcast
Oncology Endocrinology Rare diseases 
Understanding EP-NEC: Through diagnosis, treatment, and support

A medical oncologist and a patient advocate share their perspectives

Experts
Dr Aman Chauhan, Susan Meckler-Plummer, RN
Endorsed by
Minkhas mission Neuroendocrine Cancer UK Neuroendocrine Cancer Foundation
NET-Research-Foundation
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Nov 2025
  • Non-accredited Independent Medical Education
NET CONNECT GI CONNECT
Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
conference-update Conference update
Oncology 
Update from AACR–NCI–EORTC 2025: PYNNACLE Phase 2 evaluating rezatapopt in TP53 Y220C–mutant solid tumours

Clinical insights and expert discussion

Experts
Dr Alison Schram, Dr Elena Garralda
  • download Downloadable
    Resources
  • clock MIN
  • calendar Oct 2025
COR2ED
This programme has been sponsored by PMV Pharma 
podcast Video podcast
Oncology Endocrinology Rare diseases 
Exploring the role of targeted radiopharmaceutical treatment in NETs

PRRT and emerging strategies in neuroendocrine tumours

Experts
Prof. Ken Herrmann, Dr Heloisa Soares, Oncology Brothers (Moderators)
Endorsed by
NANETS
CommNETs Neuroendocrine Cancer UK
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar Oct 2025
  • Non-accredited Independent Medical Education
NET CONNECT GI CONNECT
Educational programme supported by an Independent Educational Grant from ITM.
ipcv Interactive Patient Case Video (IPCV)
Oncology 
Shared decision-making for prostate cancer patients

Early treatment intensification with a PARPi plus ARPI combination

Experts
Prof. Gunhild von Amsberg
Endorsed by
ZERO Urobel VZW | ASBL
EAUN
  • clock MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education
GU CONNECT GU NURSES CONNECT PRECISION ONCOLOGY CONNECT
Educational programme supported by an Independent Educational Grant from AstraZeneca 
conference-update Conference update
Oncology 
Oncogene-addicted NSCLC highlights from WCLC 2025

Expert insights on the latest data in oncogene-addicted non-small cell lung cancer 

Experts
Dr Devika Das
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
Lung Cancer Research Foundation
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education
LUNG CONNECT PRECISION ONCOLOGY CONNECT
Educational programme supported by an Independent Educational Grant from Bayer.
podcast Video podcast
Oncology 
Understanding the BRAFV600E testing and treatment landscapes in NSCLC

Two perspectives, one aim: A pathologist and a medical oncologist in discussion

Experts
Assoc. Prof. Umberto Malapelle, Prof. Nicolas Girard
Endorsed by
ISLB
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education
LUNG CONNECT PRECISION ONCOLOGY CONNECT
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
Explore all programmes